70415-86-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(isopropylsulfonyl)-2-nitrobenzene serves as a crucial intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications, making it an essential component in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(isopropylsulfonyl)-2-nitrobenzene is utilized as an intermediate for the production of agrochemicals. Its role in the synthesis of compounds with pesticidal properties contributes to the development of effective solutions for crop protection and management.
Used in Dye Industry:
1-(isopropylsulfonyl)-2-nitrobenzene is also employed in the dye industry, where it acts as an intermediate for the synthesis of various dyes. Its chemical properties enable the creation of dyes with specific color characteristics and applications in different industries, such as textiles and printing.
Used in Organic Synthesis:
1-(isopropylsulfonyl)-2-nitrobenzene is a valuable reagent in organic synthesis, facilitating a range of chemical reactions. Its presence of the nitro and sulfonyl groups makes it a key component in the preparation of other complex organic molecules, broadening its applications in the field of organic chemistry.
Used in Environmental and Health Risk Assessment:
As a potential environmental contaminant, 1-(isopropylsulfonyl)-2-nitrobenzene is subject to risk assessment and management. Its use in various industries necessitates proper handling and disposal to mitigate any health and environmental risks associated with its presence.

InChI:InChI=1S/C9H11NO4S/c1-7(2)15(13,14)9-6-4-3-5-8(9)10(11)12/h3-7H,1-2H3

Upstream product

• 70415-85-9 2-(isopropyl sulfanyl)nitrobenzene 
• 98-95-3 nitrobenzene 
• 88-73-3 2-Chloronitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 528-29-0 1,2-Dinitrobenzene 
• 4875-10-9 o-nitrothiophenol 
• 75-26-3 isopropyl bromide 

Downstream Products

• 76697-50-2 1-amino-2-(isopropylsulphonyl)benzene 

Relevant academic research and scientific papers

CDK inhibitor based on organic arsine as well as preparation method and application of CDK inhibitor

The invention provides a CDK inhibitor based on organic arsine as well as a preparation method and application of the CDK inhibitor. Specifically, the invention providese compounds of Formula I, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof; and the invention also discloses a preparation method and application thereof. Definitions of allgroups in the formula are shown in the specification.

CHEMICAL PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF

PROBLEM TO BE SOLVED: To provide a process for preparing ceritinib and/or intermediates thereof. SOLUTION: There is provided a process for preparing (C2-1), an intermediate of ceritinib synthesis, comprising the step of reacting (A) with (B) in a solvent in the presence of at least one catalyst, wherein P is a protecting group and T and X1 independently denote Cl and the like. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants

In order to explore novel ALK and ROS1 dual inhibitors capable of overcoming crizotinib-resistant mutants, two series of 2,4-diarylaminopyrimidine derivatives were designed, synthesized and evaluated for their in vitro cytotoxic activity. In this work, we retained the 2,4-diarylaminopyrimidine scaffold and derivatize the DAAP scaffold with sulfonyl and acrylamide moieties to extend the structure–activity relationship (SAR) study. To our delight, some compounds exhibited excellent inhibitory activity with a double-digit nanomolar level in MTT assay. Four compounds were selected for enzymic assays further, the results led to the identification of a potent ALK and ROS1 dual inhibitor X-17, with IC50 values of 3.7 nM, 2.3 nM, 8.9 nM and 1.9 nM against ALK, ALKL1196M, ALKG1202R and ROS1, respectively. Ultimately, the molecular docking studies on X-17 clearly disclosed reasonable and optimal binding interactions with ALK.

Chemical Process for Preparing Pyrimidine Derivatives and Intermediates Thereof

The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.

CHEMICAL PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF

PROBLEM TO BE SOLVED: To provide a method for producing intermediates for preparing ceritinib. SOLUTION: There is provided a method for preparing (C2-1), comprising reacting (A) with (B) in a solvent in the presence of at least one catalyst, wherein P is a protecting group and T and X1 can be independently C1 and the like. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

2,4-diarylaminopyrimidine derivative as well as preparation method and application thereof

The invention relates to a 2,4-diarylaminopyrimidine derivative shown as a general formula I and optical isomers thereof, pharmaceutically acceptable salts, solvates or prodrugs, as well as preparation methods thereof and a pharmaceutical composition taking the compound of the general formula I as an active ingredient. In the formula, substituent groups R1, R2, R3, R4, R5, R6 and X have meanings given in the description. The invention further relates to a compound of the general formula I with strong ALK and ROS1 kinase inhibition effects, and further relates to application of the compounds and optical isomers and pharmaceutically acceptable salts thereof in preparation of medicines for treating and/or preventing diseases caused by abnormal expressions of ALK and ROS1, particularly application in preparation of medicines for treating and/or preventing cancers. The structural formula is as shown in the description.

Chemical Process for Preparing Pyrimidine Derivatives and Intermediates Thereof

The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.

Including zong pyrimidine derivative and use thereof (by machine translation)

The invention relates to the general formulaIThe pyrimidine derivatives including zong shown and its optical isomer, pharmaceutically acceptable salt, solvate or prodrug, their preparation method and as shown in the formula I compound as an active ingredient of the pharmaceutical composition, wherein the substituents R1 , R2 , R3 , Ar, X has the meanings given in the specification. The invention also relates to the compounds of the general formula I has strong ALK and ROS1 kinase inhibitory activity, and also relates to the compounds and its optical isomer, a pharmaceutically acceptable salt thereof for the treatment and/or the prevention of the ROS1 ALK and of diseases caused by the abnormal expression of the pharmaceutical in the application, in particular in preparing and treating and/or preventing cancer of the use of the medicament. (by machine translation)

4-Saturated cyclosubstituted aniline protein kinase inhibitor

The invention discloses a compound being able to adjust the activity of protein kinase and used for treating or preventing protein kinase related diseases, concretely relates to a 4-saturated cyclosubstituted aniline protein kinase inhibitor belonging to a compound for adjusting the activity of anaplastic lymphoma kinase (ALK), and provides a preparation method of the compound and a pharmaceutical use of the compound in treatment or prevention of ALK related diseases.

Preparation method for ceritinib and intermediate thereof

The invention provides a preparation method for ceritinib and an intermediate thereof. The method comprises the following steps: (1) coupling the compound 1-dihydrochloride with the compound 2,5-dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidin-4-amine (a compound 3) so as to produce 5-chloro-N2-(2-isopropanolato-5-methyl-4-(piperid-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine dihydrochloride (a compound 4, i.e., ceritinib dihydrochloride); and (2) subjecting the compound 4 to dissociation so as to produce ceritinib. The preparation method provided by the invention is low in cost and high in yield, and the purity of the intermediate in each step is 99.5% or above, so high purity of ceritinib is guaranteed. The method is few in steps, simple to operate and suitable for industrial production and has great application value.